Latest Breaking News On - Head of medical affairs in europe - Page 1 : comparemela.com

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma News provided by Share this article STOCKHOLM, March 8, 2021 /PRNewswire/  Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO ), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that it strengthens the leadership of the European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon as Head of Medical Affairs Europe. The Company also announced that it opens an Early Access Program across Europe to address the significant need of new treatment alternatives in multiple myeloma. As previously announced, Oncopeptides will also seek a Conditional Marketing Authorization of melphalan flufenamide in triple class refractory multiple myeloma, during second quarter of 2021.

United statesPaula boultbeeAndrea passalacquaMartyj duvallRolf gulliksenLinda holmstrOncopeptides incGlobal head of corporate communicationsEarly access programGlobal head of medical affairsLeadership team of oncopeptidesHead of medical affairs in europeEarly access program in europeEuropean medicines agencyAccess programNasdaq stockholm